CADL — CANDEL THERAPEUTICS INC

Ownership history in EntryPoint Capital, LLC  ·  3 quarters on record

This page tracks every 13F SEC filing in which EntryPoint Capital, LLC reported a position in CANDEL THERAPEUTICS INC (CADL). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.

Peak position
0.05% (2025 Q1)
Avg. % of fund
0.04%
First filed
2025 Q1
Last filed
2025 Q3
Quarters held
3
Quarter Action Shares Change Chg % % of Fund Mkt Value Price (EOQ)
2025 Q3 ADDED 18,696 +1,453 +8.4% 0.04% $95K $5.10
2025 Q2 REDUCED 17,243 -664 -3.7% 0.04% $87K $5.06
2025 Q1 INITIATED 17,907 — — 0.05% $101K $5.65
% of Fund (quarterly)    CADL price (monthly, adj. close)

Other funds also holding CADL

As of 2025 Q4 — sorted by position size

ACORN CAPITAL ADVISORS, LLC 4.94% Halter Ferguson Financial Inc. 0.93% Portolan Capital Management, LLC 3Y 7Y 0.51% Sands Capital Alternatives, LLC 3Y 0.44% Birchview Capital, LP 3Y 7Y 0.2% Torrey Growth & Income Advisors 0.13% Tanager Wealth Management LLP 3Y 0.11% Boreal Capital Management LLC 0.07% Taylor Financial Group, Inc. 0.05% BRIDGEWAY CAPITAL MANAGEMENT, LLC 3Y 7Y 0.01%
← Back to EntryPoint Capital, LLC Holdings